PATENT COOPERATION TRE

PCT

REC'D	1 1 OCT 2004	_
WIP	DOT	_

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER AC		tion of Transmittal of International	
FP72127/AMP		Preliminary	Examination Report (Form PCT/IPEA/416)	
International application No.	International filing date (c	lay/month/year)	Priority date (day/month/year)	
PCT/US03/27370	30 August 2003 (30.08.20	003)	30 August 2003 (30.08.2003)	
International Patent Classification (IPC)	or national classification an	1 IPC		
IPC(7): G01N 33/53; C12Q 1/00; AG1K	38/00 and US Cl.: 435/7.	1, 7.2, 4; 530/317, 30	0	
Applicant				
RIGEL PHARMACEUTICALS, INC.				
This international prelimin Examining Authority and i This REPORT consists of	s transmitted to the appli	cant according to A		
·		dang this cover sin	act.	
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).				
These annexes consist of a	total of sheets.			
This report contains indicate	tions relating to the follo	wing items:		
I Basis of the report				
II Priority				
III Non-establishment of report with regard to novelty, inventive step and industrial applicability				
IV Lack of unity of invention				
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial				
applicability; citations and explanations supporting such statement				
VI Certain documents cited				
VII Certain defects in the international application				
VIII Certain observations on the international application				
Date of submission of the demand		Date of completion	of this report	
19 March 2004 (19.03.2004)		29 September 2004 (29.09.2004)		
Name and mailing address of the IPEA/US		Authorize@officer	0 00 11	
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		Jalohu	Dell-Harrigh	
P.O. Box 1450 Alexandria, Virginia 223 13-1450	j.	Felephone No. (571)	() -	
Facsimile No. (703) 305-3230		phono 140. (3/1)	212 1000	

Form PCT/IPEA/409 (cover sheet)(July 1998)



Interna	application No.	
PCT/US0	3/27370	

_		
I.	Bas	is of the report
1.	Witt	regard to the elements of the international application:*
	\boxtimes	the international application as originally filed.
	\boxtimes	the description:
		pages 1-35 as originally filed
		pages NONE , filed with the demand pages NONE , filed with the letter of .
l		
1	M	the claims:
ŀ		pages 36-41, as originally filed pages NONE, as amended (together with any statement) under Article 19
		pages NONE , filed with the demand
ĺ		pages NONE , filed with the letter of
	X	the drawings:
ļ		pages 1-7, as originally filed
		pages NONE , filed with the demand
		pages NONE, filed with the letter of
		the sequence listing part of the description:
		pages NONE, as originally filed pages NONE, filed with the demand
		pages NONE , filed with the letter of
2.	lang	h regard to the language, all the elements marked above were available or furnished to this Authority in the guage in which the international application was filed, unless otherwise indicated under this item. se elements were available or furnished to this Authority in the following language which is:
		the language of a translation furnished for the purposes of international search (under Rule23.1(b)).
		the language of publication of the international application (under Rule 48.3(b)).
		the language of the translation furnished for the purposes of international preliminary examination(under Rules 55.2 and/or 55.3).
3.		h regard to any nucleotide and/or amino acid sequence disclosed in the international application, the mational preliminary examination was carried out on the basis of the sequence listing:
		contained in the international application in printed form.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form.
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.	\boxtimes	The amendments have resulted in the cancellation of:
		the description, pages NONE
		the claims, Nos. NONE
		the drawings, sheets/fig NONE
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go
*	Da=1-	beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
thi.	s repo	ncement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in fort as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). The replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



Internation Polication No. PCT/US03/2/370

Inventive Step (IS) Claims NONE Inventive Step (IS) Claims 1-44 Claims NONE Industrial Applicability (IA) Claims 1-44 Y Claims 1-44 Y	V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Inventive Step (IS) Claims NONE Industrial Applicability (IA) Claims 1-44 Claims NONE Industrial Applicability (IA) Claims 1-44 Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that comp a chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.	1. STATEMENT				
Inventive Step (IS) Claims 1-44 Claims 1-44 Claims NONE Industrial Applicability (IA) Claims 1-44 Claims NONE Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa a chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.	Novelty (N)	Claims	1-44	YES	
Industrial Applicability (IA) Claims Claims NONE Industrial Applicability (IA) Claims Claims 1-44 Claims NONE Claims 1-44 Claims NONE Claims Claims Claims Claims 1-44 Claims Clai	140volly (14)		•	NO	
Industrial Applicability (IA) Claims					
Industrial Applicability (IA) Claims Claims 1-44 Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.	Inventive Step (IS)	Claims	1-44		
Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.		Claims	NONE	NO	
Claims NONE 2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.					
2. CITATIONS AND EXPLANATIONS Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.	Industrial Applicability (IA)	Claims	1-44		
Claims 1-44 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest methods for identifying a cyclic peptide capable of altering a phenotype of a cell comprising administering to a cell a cyclic peptide that compa chaperone binding region of known sequence and a target binding region of wholly or partially unknown sequence before assessment as claimed in the present invention. Claims 1-44 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claim can be made or used in industry.		Claims	NONE	NO	
·	can be made or used in industry.				